Sinisa Stanic1, Rebecca Paulus2, Robert D Timmerman3, Jeff M Michalski4, Robert B Barriger5, Andrea Bezjak6, Gregory M M Videtic7, Jeffrey Bradley4. 1. Carle Cancer Center and University of Illinois College of Medicine, Urbana, Illinois. Electronic address: sinisa.stanic@carle.com. 2. Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania. 3. University of Texas Southwestern, Dallas, Texas. 4. Washington University, St. Louis, Missouri. 5. Indiana University, Indianapolis, Indiana. 6. Princess Margaret Cancer Center, Toronto, Ontario, Canada. 7. Cleveland Clinic Foundation, Cleveland, Ohio.
Abstract
PURPOSE: To investigate pulmonary function test (PFT) results and arterial blood gas changes (complete PFT) following stereotactic body radiation therapy (SBRT) and to see whether baseline PFT correlates with lung toxicity and overall survival in medically inoperable patients receiving SBRT for early stage, peripheral, non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: During the 2-year follow-up, PFT data were collected for patients with T1-T2N0M0 peripheral NSCLC who received effectively 18 Gy × 3 in a phase 2 North American multicenter study (Radiation Therapy Oncology Group [RTOG] protocol 0236). Pulmonary toxicity was graded by using the RTOG SBRT pulmonary toxicity scale. Paired Wilcoxon signed rank test, logistic regression model, and Kaplan-Meier method were used for statistical analysis. RESULTS: At 2 years, mean percentage predicted forced expiratory volume in the first second and diffusing capacity for carbon monoxide declines were 5.8% and 6.3%, respectively, with minimal changes in arterial blood gases and no significant decline in oxygen saturation. Baseline PFT was not predictive of any pulmonary toxicity following SBRT. Whole-lung V5 (the percentage of normal lung tissue receiving 5 Gy), V10, V20, and mean dose to the whole lung were almost identical between patients who developed pneumonitis and patients who were pneumonitis-free. Poor baseline PFT did not predict decreased overall survival. Patients with poor baseline PFT as the reason for medical inoperability had higher median and overall survival rates than patients with normal baseline PFT values but with cardiac morbidity. CONCLUSIONS: Poor baseline PFT did not appear to predict pulmonary toxicity or decreased overall survival after SBRT in this medically inoperable population. Poor baseline PFT alone should not be used to exclude patients with early stage lung cancer from treatment with SBRT.
PURPOSE: To investigate pulmonary function test (PFT) results and arterial blood gas changes (complete PFT) following stereotactic body radiation therapy (SBRT) and to see whether baseline PFT correlates with lung toxicity and overall survival in medically inoperable patients receiving SBRT for early stage, peripheral, non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: During the 2-year follow-up, PFT data were collected for patients with T1-T2N0M0 peripheral NSCLC who received effectively 18 Gy × 3 in a phase 2 North American multicenter study (Radiation Therapy Oncology Group [RTOG] protocol 0236). Pulmonary toxicity was graded by using the RTOG SBRTpulmonary toxicity scale. Paired Wilcoxon signed rank test, logistic regression model, and Kaplan-Meier method were used for statistical analysis. RESULTS: At 2 years, mean percentage predicted forced expiratory volume in the first second and diffusing capacity for carbon monoxide declines were 5.8% and 6.3%, respectively, with minimal changes in arterial blood gases and no significant decline in oxygen saturation. Baseline PFT was not predictive of any pulmonary toxicity following SBRT. Whole-lung V5 (the percentage of normal lung tissue receiving 5 Gy), V10, V20, and mean dose to the whole lung were almost identical between patients who developed pneumonitis and patients who were pneumonitis-free. Poor baseline PFT did not predict decreased overall survival. Patients with poor baseline PFT as the reason for medical inoperability had higher median and overall survival rates than patients with normal baseline PFT values but with cardiac morbidity. CONCLUSIONS: Poor baseline PFT did not appear to predict pulmonary toxicity or decreased overall survival after SBRT in this medically inoperable population. Poor baseline PFT alone should not be used to exclude patients with early stage lung cancer from treatment with SBRT.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Yvette Seppenwoolde; Joos V Lebesque; Katrien de Jaeger; José S A Belderbos; Liesbeth J Boersma; Cees Schilstra; George T Henning; James A Hayman; Mary K Martel; Randall K Ten Haken Journal: Int J Radiat Oncol Biol Phys Date: 2003-03-01 Impact factor: 7.038
Authors: Véronique L Roger; Susan A Weston; Margaret M Redfield; Jens P Hellermann-Homan; Jill Killian; Barbara P Yawn; Steven J Jacobsen Journal: JAMA Date: 2004-07-21 Impact factor: 56.272
Authors: Ramesh Gopal; George Starkschall; Susan L Tucker; James D Cox; Zhongxing Liao; Michael Hanus; Jason F Kelly; Craig W Stevens; Ritsuko Komaki Journal: Int J Radiat Oncol Biol Phys Date: 2003-05-01 Impact factor: 7.038
Authors: Robert Timmerman; Lech Papiez; Ronald McGarry; Laura Likes; Colleen DesRosiers; Stephanie Frost; Mark Williams Journal: Chest Date: 2003-11 Impact factor: 9.410
Authors: Ying Xiao; Lech Papiez; Rebecca Paulus; Robert Timmerman; William L Straube; Walter R Bosch; Jeff Michalski; James M Galvin Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-15 Impact factor: 7.038
Authors: Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934
Authors: S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle Journal: Br J Radiol Date: 2015-04-15 Impact factor: 3.039
Authors: Michael S Kent; Sumithra J Mandrekar; Rodney Landreneau; Francis Nichols; Thomas A DiPetrillo; Bryan Meyers; Dwight E Heron; David R Jones; Angelina D Tan; Sandra Starnes; Joe B Putnam; Hiran C Fernando Journal: Ann Thorac Surg Date: 2016-04-19 Impact factor: 4.330
Authors: Stephen G Chun; Chen Hu; Hak Choy; Ritsuko U Komaki; Robert D Timmerman; Steven E Schild; Jeffrey A Bogart; Michael C Dobelbower; Walter Bosch; James M Galvin; Vivek S Kavadi; Samir Narayan; Puneeth Iyengar; Clifford G Robinson; Raymond B Wynn; Adam Raben; Mark E Augspurger; Robert M MacRae; Rebecca Paulus; Jeffrey D Bradley Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544
Authors: Shisuo Du; Virginia Lockamy; Lin Zhou; Christine Xue; Justin LeBlanc; Shonna Glenn; Gaurav Shukla; Yan Yu; Adam P Dicker; Dennis B Leeper; You Lu; Bo Lu Journal: Int J Radiat Oncol Biol Phys Date: 2016-07-21 Impact factor: 7.038
Authors: L Ceniceros; J Aristu; E Castañón; C Rolfo; J Legaspi; A Olarte; G Valtueña; M Moreno; I Gil-Bazo Journal: Clin Transl Oncol Date: 2015-08-05 Impact factor: 3.405